Literature DB >> 10648935

Antitransferrin receptor antibody-RNase fusion protein expressed in the mammary gland of transgenic mice.

D L Newton1, D Pollock, P DiTullio, Y Echelard, M Harvey, B Wilburn, J Williams, H R Hoogenboom, J C Raus, H M Meade, S M Rybak.   

Abstract

Antibodies fused to human enzymes offer an alternative to specifically targeting tumors with antibodies linked to plant or bacterial toxins. Since large amounts of these reagents can be administered without eliciting non-specific toxicities, efficient methods of production are needed. The goal of this work was to express a complex immunoenzyme fusion protein (immunotoxin) in the mammary gland of transgenic mice. A chimeric mouse/human antibody directed against the human transferrin receptor (E6) was fused at its CH2 domain to the gene for a human angiogenic ribonuclease, angiogenin (Ang). It was expressed in the mammary gland of mice and secreted into mouse milk. Expression levels in milk were approximately 0.8 g/l. The chimeric protein retained antibody binding activity and protein synthesis inhibitory activity equivalent to that of free Ang. It was specifically cytotoxic to human tumor cells in vitro.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10648935     DOI: 10.1016/s0022-1759(99)00154-4

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  10 in total

1.  Maternally derived recombinant human anti-hantavirus monoclonal antibodies are transferred to mouse offspring during lactation and neutralize virus in vitro.

Authors:  Shuyang Yu; Mifang Liang; Baoliang Fan; Hongtao Xu; Chuan Li; Quanfu Zhang; Dexin Li; Bo Tang; Shijie Li; Yunping Dai; Meili Wang; Min Zheng; Bingxue Yan; Qinghong Zhu; Ning Li
Journal:  J Virol       Date:  2006-04       Impact factor: 5.103

2.  Virus-neutralizing monoclonal antibody expressed in milk of transgenic mice provides full protection against virus-induced encephalitis.

Authors:  A F Kolb; L Pewe; J Webster; S Perlman; C B Whitelaw; S G Siddell
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

Review 3.  The transferrin receptor and the targeted delivery of therapeutic agents against cancer.

Authors:  Tracy R Daniels; Ezequiel Bernabeu; José A Rodríguez; Shabnum Patel; Maggie Kozman; Diego A Chiappetta; Eggehard Holler; Julia Y Ljubimova; Gustavo Helguera; Manuel L Penichet
Journal:  Biochim Biophys Acta       Date:  2011-08-05

Review 4.  Preparation of recombinant RNase single-chain antibody fusion proteins.

Authors:  Dianne L Newton; Susanna M Rybak
Journal:  Mol Biotechnol       Date:  2002-01       Impact factor: 2.695

5.  Expression of recombinant antibodies.

Authors:  André Frenzel; Michael Hust; Thomas Schirrmann
Journal:  Front Immunol       Date:  2013-07-29       Impact factor: 7.561

Review 6.  Updates in the Development of ImmunoRNases for the Selective Killing of Tumor Cells.

Authors:  Sandra Jordaan; Olusiji A Akinrinmade; Thomas Nachreiner; Christian Cremer; Krupa Naran; Shivan Chetty; Stefan Barth
Journal:  Biomedicines       Date:  2018-03-05

Review 7.  Transgenic milk as a method for the production of recombinant antibodies.

Authors:  D P Pollock; J P Kutzko; E Birck-Wilson; J L Williams; Y Echelard; H M Meade
Journal:  J Immunol Methods       Date:  1999-12-10       Impact factor: 2.303

Review 8.  Antibody manufacture in transgenic animals and comparisons with other systems.

Authors:  Louis Marie Houdebine
Journal:  Curr Opin Biotechnol       Date:  2002-12       Impact factor: 9.740

Review 9.  Biological Activities of Secretory RNases: Focus on Their Oligomerization to Design Antitumor Drugs.

Authors:  Giovanni Gotte; Marta Menegazzi
Journal:  Front Immunol       Date:  2019-11-26       Impact factor: 7.561

10.  Functional recombinant human anti-HAV antibody expressed in milk of transgenic mice.

Authors:  Ran Zhang; Man Rao; Chuan Li; Jingyuan Cao; Qinglin Meng; Min Zheng; Meili Wang; Yunping Dai; Mifang Liang; Ning Li
Journal:  Transgenic Res       Date:  2009-01-08       Impact factor: 2.788

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.